Preetesh Jain

Preetesh Jain is a Professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center. His research focuses on the biology and treatment of lymphoid neoplasia, with a particular emphasis on mantle cell lymphoma (MCL), including mechanisms of drug resistance and genomic alterations. His recent work has explored the role of PRMT5 as a therapeutic target, optical genome mapping of cyclin activation, and the metabolic determinants of pirtobrutinib-tolerant persister cells. He has also led clinical trials investigating frontline acalabrutinib-rituximab combinations with CAR T-cell therapy and has published extensively on outcomes following BTK inhibitor therapy and post-CAR T progression in Blood, Blood Cancer Journal, and Blood Advances.